0AB6:LSE Hyloris Pharmaceuticals S.A.

EUR 11.35 0.25 2.252252
Icon

Hyloris Pharmaceuticals S.A. (0AB6:LSE) Stock Analysis and Price Targets

COMMON STOCK | | LSE
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 11.35

+0.25 (+2.25)%

EUR 3.18M

54.00

N/A

N/A

Icon

0AB6:LSE

Hyloris Pharmaceuticals S.A. (EUR)
COMMON STOCK | LSE
EUR 11.35
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 3.18M

N/A

EUR 11.35

Hyloris Pharmaceuticals S.A. (0AB6:LSE) Stock Forecast

N/A

Based on the Hyloris Pharmaceuticals S.A. stock forecast from 0 analysts, the average analyst target price for Hyloris Pharmaceuticals S.A. is not available over the next 12 months. Hyloris Pharmaceuticals S.A.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Hyloris Pharmaceuticals S.A. is Very Bearish, which is based on 0 positive signals and 2 negative signals. At the last closing, Hyloris Pharmaceuticals S.A.’s stock price was EUR 11.35. Hyloris Pharmaceuticals S.A.’s stock price has changed by +2.25% over the past week, -12.02% over the past month and -15.30% over the last year.

No recent analyst target price found for Hyloris Pharmaceuticals S.A.
No recent average analyst rating found for Hyloris Pharmaceuticals S.A.

Company Overview Hyloris Pharmaceuticals S.A.

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. It offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advan...Read More

https://hyloris.com

Boulevard Gustave Kleyer 17, Liège, Belgium, 4000

0

December

EUR

UK

Adjusted Closing Price for Hyloris Pharmaceuticals S.A. (0AB6:LSE)

Loading...

Unadjusted Closing Price for Hyloris Pharmaceuticals S.A. (0AB6:LSE)

Loading...

Share Trading Volume for Hyloris Pharmaceuticals S.A. Shares

Loading...

Compare Performance of Hyloris Pharmaceuticals S.A. Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for 0AB6:LSE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Hyloris Pharmaceuticals S.A. (Sector: )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
0R2V:LSE
Apple Inc. +1.40 (+0.81%) EUR9,223,372,036.85B 30.58 N/A

ETFs Containing 0AB6

Symbol Name 0AB6's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Hyloris Pharmaceuticals S.A. (0AB6:LSE) Stock

Stock Target Advisor's fundamental analysis for Hyloris Pharmaceuticals S.A.'s stock is Very Bearish.

Unfortunately we do not have enough data on 0AB6:LSE's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on 0AB6:LSE's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on 0AB6:LSE's stock to indicate if its overvalued.

The last closing price of 0AB6:LSE's stock was EUR 11.35.

The most recent market capitalization for 0AB6:LSE is EUR 3.18M.

Unfortunately we do not have enough analyst data on 0AB6:LSE's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Hyloris Pharmaceuticals S.A.'s stock.

As per our most recent records Hyloris Pharmaceuticals S.A. has 0 Employees.

Hyloris Pharmaceuticals S.A.'s registered address is Boulevard Gustave Kleyer 17, Liège, Belgium, 4000. You can get more information about it from Hyloris Pharmaceuticals S.A.'s website at https://hyloris.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...